Streetbeat News

Regulatory

ALLR

Allarity Therapeutics' shares surged following the announcement that its stockholders' equity exceeds the $2.5 million Nasdaq minimum requirement. The company plans to request the SEC to withdraw Form S-1.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:50 pm

HOOD

Robinhood expressed disappointment after the SEC issued a 'Wells Notice', indicating potential regulatory action. The company firmly believes that the assets listed on its platform are not securities, suggesting a disagreement with the SEC's stance.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:46 pm

CYBN

Cybin Inc. (CYBN) announced updates on its clinical programs, including the expected initiation of a Phase 3 study for CYB003 in MDD by mid-2024 and Phase 2 results for CYB004 in GAD by Q4 2024. The company secured a $150 million funding round and received FDA Breakthrough Therapy Designation for CYB003. CYB003 showed promising Phase 2 results in MDD treatment, and CYB004 is in development for GAD, with a Phase 2 study underway. Cybin's intellectual property portfolio includes over 50 granted patents and 170 pending applications related to psychedelic-based treatments.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:42 pm

KULR

KULR Technology Group, Inc. (NYSE:KULR) has regained compliance with NYSE American's continued listing standards, resolving a deficiency related to the low selling price of its common stock. The company achieved sustained price improvement, reflecting its commitment to enhancing stockholder value and optimizing long-term public valuation.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:40 pm

RDFN

Redfin has agreed to a proposed settlement of $9.25 million to resolve the nationwide class action litigation, Gibson v. NAR, No. 4:23-cv-00788. The settlement requires Redfin to pay into a Qualified Settlement Fund within 30 days following the court's preliminary approval of the settlement agreement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:38 pm

JAGX

The FDA has conditionally approved Jaguar Health's prescription drug Crofelemer for treating chemotherapy-induced diarrhea in dogs. Diarrhea is a leading cause for veterinary visits, with no FDA-approved anti-secretory agents available for treatment until now.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:35 pm

NRXP

NRx Pharmaceuticals announced the final results of its clinical trial, indicating that its drug NRX-101 has shown to reduce akathisia while maintaining comparable antidepressant efficacy. The company believes these results may constitute a basis for seeking accelerated FDA approval for NRX-101.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm

HOOD

Robinhood Crypto, a subsidiary of Robinhood Markets, Inc. (HOOD), received a Wells Notice from the SEC on May 4, 2024, indicating a preliminary determination to recommend enforcement action for alleged violations of securities laws. This follows investigative subpoenas regarding cryptocurrency listings, custody, and platform operations. The SEC's action could include a range of remedies such as injunctions, penalties, and limitations on activities.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:33 pm

PRCT

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced long-term, real-world data demonstrating the sustained benefits of Aquablation therapy for treating benign prostatic hyperplasia (BPH). The data, presented at the American Urological Association Annual Meeting, showed significant improvements in prostate volume, urinary flow rate, and symptom scores across multiple studies. The therapy was effective across a range of prostate sizes with a low rate of surgical retreatment, highlighting its safety and durability.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:22 pm

OM

Outset Medical has received FDA 510(k) clearance for its TabloCart with prefiltration, marking a significant regulatory milestone for the company. This approval could enhance the company's product offerings in the medical device sector, potentially impacting its market position and investor sentiment positively.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:16 pm